AMRI Announces Appointment of William Marth as Chairman of the Board of Directors

   AMRI Announces Appointment of William Marth as Chairman of the Board of
                                  Directors

  PR Newswire

  ALBANY, New York, June 5, 2013

ALBANY, New York, June 5, 2013 /PRNewswire/ --AMRI (NASDAQ: AMRI), a leading
global contract research and manufacturing organization, has announced that
the Board of Directors has unanimously voted to separate the role of Chairman
and Chief Executive Officer and has named William S. Marth, an active member
of the AMRI Board of Directors, as Chairman of the Board, effective June 5,
2013. The position of Chairman has been held by Thomas E. D'Ambra, Ph.D. since
the Company's founding.

(Logo: http://photos.prnewswire.com/prnh/20120229/NY61160LOGO )

Dr. D'Ambra retains his roles as a member of the Board of Directors, President
and CEO. Mr. Marth was appointed to the AMRI Board of Directors in 2012,
joining Veronica G. H. Jordan, Ph.D.; Gabriel Leung; Kevin O'Connor; Arthur J.
Roth; and Una S. Ryan, O.B.E., Ph.D.

Mr. Marth said, "AMRI maintains a unique and strong position providing a broad
range of drug discovery, development and manufacturing services to the
pharmaceutical, biotechnology and related industries. I have been impressed
with the Company's accomplishments and potential and look forward to
contributing to growing both the depth and breadth of AMRI's services in my
role as Chairman."

Dr. D'Ambra said, "Bill is an accomplished and visionary industry leader who
has an unparalleled record of commercial success. Since joining the Board
approximately one year ago, he has been very helpful to me personally as well
as to the Company. I am confident with Bill as our Chairman, that the Company
is poised for continued and greater success. I, along with the rest of the
members of the Board of Directors, look forward to continuing to serve with
Bill on behalf of all AMRI shareholders. AMRI's success has been built on a
reputation for the highest quality standards in its work and ethics. Our
corporate governance structure demonstrates AMRI's commitment to sustaining a
superior level of performance."

Mr. Marth, formerly President and Chief Executive Officer of Teva – Americas,
retired from Teva in 2012. He had previously served as President and Chief
Executive Officer of Teva North America from January 2008 to June 2010 and
prior to that as President and Chief Executive Officer of Teva USA. He was
previously Executive Vice President and Vice President of Sales and Marketing
for Teva USA.

Mr. Marth played a significant role in establishing Teva as a leading
Specialty Pharmaceutical company and being ultimately recognized as the
worldwide No. 1 producer of generic drugs. In his role, he led respiratory,
neuroscience, oncology and women's healthcare divisions, as well as Latin
America and Canada. He was a member of Teva's global executive management team
and Teva Americas' board of directors since 2007. He brings to this role his
global experience in Strategic Planning, IR, R&D, Supply Chain and Regulatory.
He was the architect of the $6.8 billion Cephalon and $7.4 billion Barr
Laboratories acquisitions. Prior to joining Teva USA, he held various
positions with the Apothecon division of Bristol-Myers Squibb.

Mr. Marth, who earned his B.Sc. in Pharmacy from the University of Illinois in
1977 and his M.B.A. in 1989 from the Keller Graduate School of Management,
DeVry University, is a licensed pharmacist and serves on various other boards
and committees, including The University of the Sciences in Philadelphia and
the Board of Ambassadors for John Hopkins' Project RESTORE. In addition, Mr.
Marth served as the Chairman of the Board of the Generic Pharmaceutical
Association (GPhA) in 2008 and 2009 and the American Society for Health-System
Pharmacists (ASHP) in 2010.

About AMRI

Albany Molecular Research, Inc. (AMRI) is a global contract research and
manufacturing organization offering customers fully integrated drug discovery,
development and manufacturing services. For over 21 years, AMRI has
demonstrated its adaptability as the pharmaceutical and biotechnology
industries have undergone tremendous change in response to multiple
challenges. This experience, a track record of success and locations in the
United States, Europe and Asia now provides our customers with SMARTSOURCING™,
a full range of value-added opportunities providing customers informed
decision-making, enhanced efficiency and more successful outcomes at all
stages of the pipeline. AMRI has also successfully partnered R&D programs and
is actively seeking to out-license its remaining programs for further
development. For more information about AMRI, please visit our website at
www.amriglobal.com or follow us on Twitter ( @amriglobal ).

Website: http://www.amriglobal.com
Contact: Investors: Michael Nolan, AMRI Chief Financial Officer,
+1-518-512-2261; or Media: Gina Monari, AMRI Communications, +1-518-512-2512
 
Press spacebar to pause and continue. Press esc to stop.